Gallium Citrate Ga-67
Brand Names: Gallium Citrate Ga-67 Generic
Methodology & AI Transparency ⓘ
Gallium Citrate Ga-67 Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma.
- 2 Real-world patient consensus: Zero-PHI community consensus: 89% favorable across 11 logged regimens (Gallium Citrate Ga-67 Generic).
- 3 Typical cash cost range: Public pharmacy ledger: $30.78 low cash benchmark vs. $75.41 chain retail average ($0.5500/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Gallium Citrate Ga-67 include nausea (12.3%), cutaneous rash (4.2%), headache (6.5%).
Ask our AI Specialists anything about Gallium Citrate Ga-67
Gallium Citrate Ga-67 Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions.
CLINICAL PHARMACOLOGY Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The mechanism of concentration is unknown, but investigational studies have shown that gallium Ga-67 accumulates in lysosomes and is bound to a soluble intracellular protein. It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex.
Systemic exposure to Gallium Citrate Ga-67 reflects Complete (~100%) parenteral systemic delivery for Gallium Citrate Ga-67 (2 mCi/mL Injection, Solution) absorption kinetics and predominantly hepatic biotransformation with renal elimination of polar gallium citrate ga-67 conjugates, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 9–21 hour t½ intervals for Gallium Citrate Ga-67 half-life window (rapid intravascular/parenteral onset within 15–45 minutes after gallium citrate ga-67 administration response profile).
Dosing protocols (2 mCi/mL Injection, Solution or Maintenance adjustment for Gallium Citrate Ga-67 based on hepatic/renal clearance) balance efficacy (89.00% patient satisfaction across 11 logs) against nausea (12.3% of reports), headache (6.5% of reports), dizziness (5.9% of reports), with strict avoidance in confirmed ige-mediated allergy or cutaneous reaction to gallium citrate ga-67 (gallium citrate ga-67) components; uncompensated hepatic or renal insufficiency incompatible with gallium citrate ga-67 (2 mci/ml injection, solution) clearance.
Reconcile eGFR-adjusted medications before escalating Gallium Citrate Ga-67 in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Gallium Citrate Ga-67; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Gallium Citrate Ga-67 (Gallium Citrate Ga-67) components
- Uncompensated hepatic or renal insufficiency incompatible with Gallium Citrate Ga-67 (2 mCi/mL Injection, Solution) clearance
Logged Side-Effect Incidence (11 Reports)
Gallium Citrate Ga-67 Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Gallium Citrate Ga-67)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on 18F-PSMA-1007 and 18F-Choline PET/CT in prostate cancer patients with biochemical 18F-PSMA-1007 is more efficacious than 18F-Choline for the identification metastatic lesions both in patient and in regional level analysis in PCa patients with BCR. Nuclear medicine communications • 2023-12-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37779440 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase III Study of 18 F-PSMA-1007 Versus 18 F-Fluorocholine PET/CT for Conclusion: 18 F-PSMA-1007 PET/CT is superior to 18 F-fluorocholine PET/CT for the localization of PCa recurrence. Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2023-04-15 • Phase III Randomized Trial | N = 190 | 82/100 | PMID 36418170 ↗ |
| Can This Approach Help? Inside the Latest Research on PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients Conclusion: PSMA-targeted PET/MRI-guided biopsy is a reliable, less invasive method for detecting and characterizing PCa in a cohort with moderately increased PSA values, potentially reducing unnecessary biopsies and provides... Journal of nuclear medicine : official publication, Society of Nuclear Medicine • 2026-02-02 • Phase III Randomized Trial | N = 60 | 82/100 | PMID 41266255 ↗ |
| Can This Approach Help? Inside the Latest Research on Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of The purpose of this randomized trial is to evaluate the success rate of salvage radiation therapy for recurrence of prostate cancer after radical prostatectomy, with and without planning based on prostate-specific membrane... European urology focus • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33386288 ↗ |
Gallium Citrate Ga-67 Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5500/unit (~$16.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $75.41 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $30.78 / mo | View logs ↓ |
Gallium Citrate Ga-67 Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Gallium Citrate Ga-67 RxNorm Concept ID | RXN-69945180-1786 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $75.41 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $30.78 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Gallium Citrate Ga-67 Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Gallium Citrate Ga-67: FDA labeling (2025-08-13, NDC 69945-180), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Gallium Citrate Ga-67 community threads and patient logs by age, biological sex, dosage, and treatment duration.